Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1675P - Potential effect of adipose tissue distribution on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients (pts) receiving first-line pembrolizumab (PEMBRO)

Date

16 Sep 2021

Session

ePoster Display

Presenters

Ilaria Trestini

Citation

Annals of Oncology (2021) 32 (suppl_5): S1175-S1198. 10.1016/annonc/annonc714

Authors

I. Trestini1, M. Cintoni2, M. Sposito1, D. Kadrija1, A. Dodi1, A. Caldart1, L. Belluomini1, J. Menis1, E. Vita3, I. Sperduti4, A. Drudi5, G. Aluffi5, D. Tregnago1, A. Avancini6, M. D'Onofrio5, M.C. Mele7, G. Tortora3, M. Milella1, E. Bria3, S. Pilotto1

Author affiliations

  • 1 Section Of Oncology, University of Verona Hospital Trust, 37134 - Verona/IT
  • 2 Scuola Di Specializzazione In Scienza Dell'alimentazione, Università di Roma Tor Vergata, Rome/IT
  • 3 Medical Oncology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica Del Sacro Cuore, Rome/IT
  • 4 Biostatistics Unit, IRCCS Regina Elena National Cancer Institute, Rome/IT
  • 5 Department Of Radiology, University of Verona Hospital Trust, Verona/IT
  • 6 Biomedical Sciences, University of Verona, Verona/IT
  • 7 Uosa Di Nutrizione Avanzata In Oncologia, Dipartimento Di Scienze Mediche E Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome/IT
More

Abstract 1675P

Background

Body composition (BC)-related phenotypes, including loss of muscle mass and fat tissue distribution, have been suggested to potentially modulate immunotherapy outcomes in lung cancer pts. In this light, our study aimed to evaluate BC and its potential correlations with ECOG PS, comorbidities, and survival outcomes in NSCLC pts receiving first-line PEMBRO.

Methods

A retrospective analysis of consecutive advanced NSCLC pts treated with PEMBRO as first-line therapy at two academic medical institutions from August 2017 to August 2020 was performed. The area (cm2) and density (Hounsfield Units [HU]) of skeletal muscle and adipose tissue (subcutaneous [SAT], visceral and intermuscular) were measured on pre-treatment computed tomography scans at the level of the third lumbar vertebra. Data were correlated to progression-free/overall survival (PFS/OS) using a Cox and logistic regression model. Log-Rank analysis was used for Kaplan-Meier curves comparison.

Results

Data from 77 pts was gathered, with a median follow-up of 11 months (range 1-42). Forty (51.9%) pts were former smokers and 27 (35.1%) current smokers. ECOG PS was 0-1 in 56 (72.7%) pts and ≥2 in 21 pts (27.3%). Comorbidities were reported in 49 (63.6%) pts. All BC parameters were significantly correlated with the presence of comorbidities and ECOG PS. Median PFS and OS were 3 (95% CI, 2-4) and 10 (95% CI, 8-13) months, respectively. At univariate analysis, high SAT negatively correlated with PFS. Pts with pre-treatment SAT<143 had significantly longer 6-month PFS (median 8 vs. 3 months, p = 0.05). Although BC parameters were not associated with OS, this was numerically shorter in those pts with higher SAT (median 12 vs. 18 months, p = 0.11).

Conclusions

These preliminary results support the hypothesis that BC may impact on survival of advanced NSCLC pts treated with PEMBRO, suggesting a potential interaction between immune system and BC. Further analyses are ongoing in this pts’ cohort in order to monitor BC changes during treatment, as well as to explore the biological rational supporting the emerging close relationship between immune system and nutritional parameters.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M. Milella: Other, Personal, Invited Speaker: EUSA Pharma, Pfizer, MSD, AstraZeneca, Merck Serono and Mylan. E. Bria: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis and Roche. S. Pilotto: Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca, Eli-Lilly, BMS, Boehringer Ingelheim, MSD and Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings